Unfortunately, most patients treated with TKs, such as dasatinib and imatinib, experience leukemia cell persistence in CML because the leukemia stem cells (CD34 + CD38-) enter the G0 phase, in which the cells become quiescent, and can thus survive. This evidence concerns the gene CD38 and chronic myelogenous leukemia, BCR-ABL1 positive.